vinorelbine 10 base mg/ml concentrate for soln for inf
flynn pharma ltd - vinorelbine tartrate - concentrate for soln for inf - 10 base mg/ml
vinorelbine martindale pharma 10 mg/ml concentrate for soln for inf
cardinal health uk 434 limited - vinorelbine tartrate - concentrate for soln for inf - 10 mg/ml
dbl vinorelbine 50mg/5ml (as tartrate) concentrated injection vial
hospira australia pty ltd - vinorelbine tartrate -
dbl vinorelbine 10mg/1ml (as tartrate) concentrated injection vial
hospira australia pty ltd - vinorelbine tartrate -
vinorelbine strides 10 mg/ml concentrate for soln for inf
strides arcolab international limited - vinorelbine tartrate - concentrate for soln for inf - 10 mg/ml
vinorelbine alvogen soft capsules 20mg
lotus international pte. ltd. - vinorelbine tartrate eqv. vinorelbine - capsule, liquid filled - vinorelbine tartrate eqv. vinorelbine 20.00 mg
vinorelbine alvogen soft capsules 30mg
lotus international pte. ltd. - vinorelbine tartrate eqv. vinorelbine - capsule, liquid filled - vinorelbine tartrate eqv. vinorelbine 30.00 mg
vinorelbine 10mg/1ml concentrate for solution for infusion vials
medac uk - vinorelbine tartrate - solution for infusion - 10mg/1ml
vinorelbine 50mg/5ml concentrate for solution for infusion vials
medac uk - vinorelbine tartrate - solution for infusion - 10mg/1ml
hospira vinorelbine tartrate 50 mg/5 ml injection vial
hospira australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml - injection - excipient ingredients: water for injections - vinorelbine is indicated as a single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced nonsmall cell lung cancer (nsclc). in patients with stage iv nsclc, vinorelbine is indicated as a single agent or in combination with cisplatin. in stage iii nsclc, vinorelbine is indicated in combination with cisplatin.